Please assess the completion status of the following clinical trial:

Trial Title: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver cirrhosis~* ACLF grade 1, 2 or 3 (Canonic criteria)~* Signed informed consent~Exclusion Criteria:~* Acute or subacute liver failure without cirrhosis~* ACLF grade 1 with response to medical therapy~* Evidence of current malignancy including hepatocellular carcinoma (any grade) or alphafetoprotein \> 400 ng/ml~* Previous personal history of malignancy (active or in complete remission) or familiar history of hereditary cancer.~* Moderate or severe chronic heart failure (NYHA III-IV)~* Renal replacement therapy~* Severe chronic pulmonary disease (GOLD III-IV)~* Gastrointestinal bleeding in the last 5 days~* Previous liver transplantation~* Immunosuppressive therapy~* Extrahepatic cholestasis~* HIV infection~* Pregnant of breastfeeding women~* Pre-menopausal women who are of child bearing potential and are not practicing an acceptable method of birth control.~* Participation in any investigational trial in the last 3 months~* Active addition to illegal drugs~* Refusal to participate~* Patients who can not provide prior informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Allogenic Mesenchymal stem cells (Type: EXPERIMENTAL): Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
- Placebo (Type: PLACEBO_COMPARATOR): Solution without cells on days 1, 4, 11 and 18

Based on this trial design, predict the completion outcome and termination type (if applicable).